APA

Martinez-Majander N., Ntaios G., Liu Y. Y., Ylikotila P., Joensuu H., Saarinen J., Perera K. S., Marti-Fabregas J., Chamorro A., Rudilosso S., Prats-Sanchez L., Berkowitz S. D., Mundl H., Themeles E., Tiainen M., Demchuk A., Kasner S. E., Hart R. G. & Tatlisumak T. (20210621). Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. : European journal of neurology.

Chicago

Martinez-Majander N, Ntaios G, Liu Y Y, Ylikotila P, Joensuu H, Saarinen J, Perera K S, Marti-Fabregas J, Chamorro A, Rudilosso S, Prats-Sanchez L, Berkowitz S D, Mundl H, Themeles E, Tiainen M, Demchuk A, Kasner S E, Hart R G and Tatlisumak T. 20210621. Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. : European journal of neurology.

Harvard

Martinez-Majander N., Ntaios G., Liu Y. Y., Ylikotila P., Joensuu H., Saarinen J., Perera K. S., Marti-Fabregas J., Chamorro A., Rudilosso S., Prats-Sanchez L., Berkowitz S. D., Mundl H., Themeles E., Tiainen M., Demchuk A., Kasner S. E., Hart R. G. and Tatlisumak T. (20210621). Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. : European journal of neurology.

MLA

Martinez-Majander N, Ntaios G, Liu Y Y, Ylikotila P, Joensuu H, Saarinen J, Perera K S, Marti-Fabregas J, Chamorro A, Rudilosso S, Prats-Sanchez L, Berkowitz S D, Mundl H, Themeles E, Tiainen M, Demchuk A, Kasner S E, Hart R G and Tatlisumak T. Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. : European journal of neurology. 20210621.